

PERSONAL  
INFORMATION



Arsalan Amirfallah



Skógarvegur 20, No 105, 103 Reykjavik, Iceland.



003545438031



003547853723



[arsalan@landspitali.is](mailto:arsalan@landspitali.is)

[ara54@hi.is](mailto:ara54@hi.is)

[arsalan.amirfallah@gmail.com](mailto:arsalan.amirfallah@gmail.com)

Sex Male | Date of birth 17/01/1981 | Nationality Iranian

**Current Position:** PhD student at University of Iceland, Faculty of Medicine, Biomedical Center, Landspítali University Hospital, Department of Pathology, Cell biology unit, Reykjavik, Iceland

EDUCATION

---

**01/11/2015-**

PhD student at University of Iceland, Faculty of Medicine, and Biomedical Center

**Title of thesis:** Identification of Potential Novel Genes in Breast Cancer correlated with Progression.

**09/02/2011-02/08/2013**

M.Sc. in Basic oncology,

Institute of Health Science, Department of Basic Oncology Dokuz Eylül University, Izmir, Turkey,

**Title of Thesis:** “Polymorphic Characteristics of Enzymes that Metabolize Anticancer Drugs”

**01/09/1999-01/09/2005**

Doctorate of Veterinary Medicine (DVM),

Institute of health science faculty of Veterinary medicine Urmia Islamic Azad University, Urmia, Iran

**Title of thesis:** “Usage of dopamine agonists (Cabergoline) for estrus induction in Dogs

WORK EXPERIENCE

---

**12/2015-**

PhD student

Landspítali University Hospital, Department of Pathology, Cell Biology Units, Reykjavik, Iceland.

**11/2014-01/2015**

Research Assistant

CRO-National Cancer Institute, Experimental and Clinical Pharmacology Unit, Aviano, PN, Italy, [www.cro.it](http://www.cro.it)

**06/2014-09/2014**

Visiting Researcher

Institute for Pharmaco- & Toxicogenomics, Hannover Medical School, Hannover, Germany, [www.mh-hannover.de](http://www.mh-hannover.de)

**07/2011-09/2011**

Lab Staff

Azerbaijan Hospital, Medical Laboratories, Pathology Division, Orumieh, Iran, [www.azarbajjanhospital.com](http://www.azarbajjanhospital.com)

**09/2006-09/2010**

Veterinarian, Iranmehr Pet Clinic, Orumieh, Iran

**HONORS AND AWARDS** \_\_\_\_\_

**2013:** Second degree award among all graduated, Health Sciences M.Sc. students in Dokuz Eylul University.

**2012:** First prize for best poster presentation with “Are you aware? Cancer says that I'm coming: Skin Cancer”, Dokuz Eylul University Special Study Module Symposium (28th September 2012, Izmir-Turkey).

**2011:** First prize for best poster presentation with “Effect of KRAS mutations in colorectal cancer Treatment”, Third Annual Science Fair of Dokuz Eylul University School of Medicine- Current Approaches in Oncology, 7th-9th October, 2011.

**PUBLICATIONS** \_\_\_\_\_

**PEER-REVIEWED JOURNAL ARTICLES AND INVITED BOOK CHAPTERS**

1. Baskin Y, Calibasi G, **Amirfallah A**, Dagdeviren YK, Canda AE, Sarioglu S, Sagol O, Ellidokuz H, Oztop I, Yilmaz U. **KRAS and BRAF mutation frequencies in a series of Turkish colorectal cancer patients**. Translational Cancer Research Journal, 3(2), April 2014.
2. Baskin Y, **Amirfallah A**, Calibasi G, Olgun N. **Hepatopathy-Thrombocytopenia Syndrome During Actinomycin D Treatment May Be Related to MDR1 (ABCB1)**

**Gene Polymorphisms.** Am JTher. Jan 9, 2014.

3. Baskin Y, **Amirfallah A**, Unal OU, Calibasi G, Oztop I. **Dihydropyrimidine Dehydrogenase 85T>C Mutation Is Associated With Ocular Toxicity of 5-Fluorouracil: A Case Report**, Am J Ther. 2015 Mar-Apr; 22(2):e36-9.doi: 10.1097/MJT.0b013e31829e8516.
4. **Arsalan Amirfallah**, Yasemin Baskin, Clinical Biochemistry, **Sample collection and Pre Analytical Variables**, Nobel Kitab Evi, 19-26, ISBN NO: 97860558452107 (2015).
5. C. Hizel, Sukru Tuzmen, **A. Amirfallah**, G. Çalibaşı Koçal, D. Abbasoglu, Yasemin Baskin, **Precision medicine in colorectal cancer**, Precision Medicine in Cancers and Non-Communicable Diseases, Barh D Ed, Taylor &Francis, Identifiers: LCCN 2018014610| ISBN 9781498775601 (hardback : alk. paper) | ISBN 9781315154749 (ebook) (2018).
6. **Amirfallah A**, Kocal GC , Unal OU, Ellidokuz H, Oztop I, Basbinar Y, **DPYD, TYMS and MTHFR Genes Polymorphism Frequencies in a Series of Turkish Colorectal Cancer Patients**, J Pers Med. 2018 Dec 13;8(4). pii: E45. doi: 10.3390/jpm8040045.
7. **Arsalan Amirfallah**, Adalgeir Arason, Hjorleifur Einarsson, Eydis T. Gudmundsdottir, Edda S. Freysteinsdottir, Krístrun Olafsdottir, Oskar Þor Johannsson, Bjarni A. Agnarsson, Rosa Bjork Barkardottir, Inga Reynisdottir, **High expression of the Vacuole Membrane Protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer**,(Under Review ).

## CONFERENCE PRESENTATIONS

---

### TALKS

1. **Arsalan Amirfallah**, Yasemin Baskin, Gizem Calibasi, H.Nur Olgun, **Importance of Multidrug Resistance Gene 1 (MDR 1) in Personalized Cancer Treatment**, International Symposium on Advances in Predictive & Personalized Medicine ( Oral Presentation), April 2-3 2015, Istanbul Turkey.
2. **Arsalan Amirfallah**, Eydís Þ. Guðmundsdóttir, Adalgeir Arason, Bjarni A. Agnarsson, Óskar Þór Jóhannsson, Rósa Björk Barkardóttir, and Inga Reynisdóttir, **Potential Role of an Autophagy Gene in Breast Tumor Development**, IceBio2017 – The biannual Conference on Biology in Iceland 26-28 October 2017, Reykjavik, Iceland.

### POSTERS

1. Yasemin Baskin, **Arsalan Amirfallah**, Gizem Calibasi, Ilhan Oztop, **Pharmacogenomics Approach to 5-Fluorouracil (5-FU)-based Chemotherapy; A Personalized Cancer Management Experience in Dokuz Eylül University**,

International Symposium on Advances in Predictive & Personalized Medicine ( Oral Presentation), April 2-3 2015, Istanbul Turkey.

2. Yasemin Baskin, Kagan Dagdeviren, Gizem Calibasi, **Arsalan Amirfallah**, Hulya ellidokuz, **Pharmacogenomics and Pharmacoconomics**, IVEK International Drug and Pharmaceutics Congres ( Poster Presentation) , 28-30 November 2014, Istanbul Turkey.
3. Eskiizmir G, Akbarpour M, Calibasi G, **Amirfallah A**, Ellidokuz H. Baskin Y. **Serum Biomarkers for Head and Neck Squamous Cell Carcinoma**. 17th, Fritz- Bender-Foundation International Syposium: Progress Towards Individulised Cancer Treatments, (Poster presentation), November, 2013, Barcelona, Spain.
4. **Amirfallah A**, Baskin Y, Calibasi G, Unal OU, Ellidokuz H, Oztop I. **MTHFR 677 C>T mutation contributing to 5-fluorouracil mediated toxicity especially hand and foot syndrome**. 17th, Fritz- Bender-Foundation International Syposium: Progress Towards Individulised Cancer Treatments, (Poster presentation), November, 2013, Barcelona, Spain.
5. **Arsalan A**, Baskin Y, Calibasi G, Unal OU, Oztop I, Ellidokuz H. **Genetic polymorphisms of 5-fluorouracil metabolic pathway related enzymes in the Turkish population**. 17th, Fritz- Bender- Foundation International Syposium: Progress Towards Individulised Cancer Treatments, (Poster presentation), November, 2013, Barcelona, Spain.
6. Baskin Y, Calibasi G, **Amirfallah A**, Sarioglu S, Ellidokuz H. **Comparison of KRAS genotyping methodologies: Dokuz Eylul University Molecular Oncology Laboratory Experience**. IFCC, EFCC Euro Med Lab Milano, (Poster presentation), May 19th - 23th 2013.
7. **Amirfallah A**, Çalıbaşı G, Dağdeviren YK, Baskın Y. **Multi-Drug Resistance in Cancer Treatment**. First Congress of the public sector pharmacists, (Poster presentation), 6th-9th December 2012, Antalya- Turkey.
8. **Amirfallah A**, Çalıbaşı G, Baskın Y. **Pharmacogenetic approach to follow-up treatment of anticancer drugs**. First Congress of the public sector pharmacists, (Poster presentation), 6th-9<sup>th</sup> December 2012, Antalya- Turkey.
9. Yigitbasi T, Baskin Y, Çalıbaşı G, **Amirfallah A**, Dagdeviren , Yigitbasi G. **The dose-dependent variable effects of carvacrol on the cell proliferation**. IV. Multidiciplinary

Cancer Research Symposium, (Poster presentation), 13th -16th December 2012, Bursa, Turkey.

10. Baskin Y, Calibasi G, **Amirfallah A**, Yigitbasi T. **Real-Time cytotoxicity assay and/ or cell proliferation assay**. IV.Multidiciplinary Cancer Research Symposium, (Poster presentation), 13th -16th December 2012, Bursa, Turkey.
11. **Amirfallah A**, Baskin Y, Calibasi G, Nur Olgun H. **Role of MDR1 (P-glycoprotein, ABCB1) in personalized cancer treatments: with a clinical experience**. IV.Multidiciplinary Cancer Research Symposium, (Poster presentation), 13th - 16th December 2012, Bursa, Turkey.
12. Calibasi G, **Amirfallah A**, Baskin Y, Sarioglu S, Sagol O, Oztop I, Ellidokuz H, Yilmaz U. **The Relationship between Kras- Braf Mutations and Resistance To Anti- Egfr Therapies In Colorectal Cancer**. 2nd ISC Conference on Innovative Therapies-New Targets, New Challenges, New Drugs" Istanbul on 2-4 November 2012.
13. **Amirfallah A**, Calibasi G, Unal OU, Baskin Y, Oztop I, Ellidokuz H, Yilmaz AU. **5-Fluorouracil Metabolic Pathway Genetic Polymorphisms Were Associated With Treatment Related Toxicity: Pharmacogenomic Analysis**. 2nd ISC Conference on Innovative Therapies-New Targets, New Challenges, New Drugs" Istanbul on 2-4 November 2012.
14. Baskin Y, Calibasi G, **Amirfallah A**, Gurel Duygu, Oztop I. **The frequency of EGFR mutations with non-small cell lung cancer in aegean part of turkey**. 24th National Congress of Biochemistry 25th- 28th September, 2012 Konya, Turkey.
15. **Amirfallah A**, Çalibaşı G, Ellidokuz H, Olgun N, Baskin Y. **Polymorphisms characteristics of enzymes (CYP2C9,CYP2C8,ALDH1A, ALDH3A1) in cyclophosphamide metabolic pathway**. 24th National Congress of Biochemistry 25th-28th September 2012, Konya, Turkey.
16. yanık T, Uyanık G, **Amirfallah A**, Çalibaşı G, Özcan Keskin A, Kayacık N, Baskin Y. **KRAS Mutation Status is Associated With Anti- EGFR Therapy Resistance in Metastatic Colorectal Cancer**. EACR –Anticancer Agents Reserach Congress, (Poster presantation),13-16 October 2011, Izmir, Turkey.

17. Uyanık G, Uyanık T, Çalıbaşı G, **Amirfallah A**, Kayacık N, Özcan Keskin A, Baskın Y. **From Genotype to Tumour Behavior: Colon Malignant Neoplasm.** EACR–Anticancer Agents Research Congress, 13-16 October 2011, Izmir, Turkey.
18. **Arsalan Amirfallah**, Harpa Lind Björnsdóttir, Hjörleifur Einarsson, Eydís Þ. Guðmundsdóttir, and Inga Reynisdóttir, **Validation of gene fusions found through in silico analysis in breast cancer cell lines**, The 18th Conference on Research in Biomedical and Health Sciences, 3 -4 January 2017, Reykjavik, Iceland.
19. **Arsalan Amirfallah**, Adalgeir Arason, Bjarni A. Agnarsson, Óskar Þór Jóhannsson, Rósa Björk Barkardóttir and Inga Reynisdóttir, **Comparison of Expression of miR21's Guide Strand (5P) and Passenger Strand (3P) in Breast Tumor Progression**, 25th Biennial Congress of the European Association for Cancer Research (EACR25) 30 June - 03 July 2018, Amsterdam, Netherlands.
20. **Arsalan Amirfallah**, Adalgeir Arason, Hjörleifur Einarsson , Eydis T. Gudmundsdottir, Oskar Þor Johannsson, Bjarni A. Agnarsson, Rosa Bjork Barkardottir, Inga Reynisdottir, **Potential Clinical Significance of Vacuole Membrane Protein 1 (VMP1) expression in Breast Tumour Progression**, 33rd Genes and Cancer Annual Meeting 2019, 8th - 11th April 2019, Robinson College, Cambridge, UK.

#### ATTENDED COURSES

1. As a participant in, theoretical course in CURRENT ISSUES CANCER Biology organized by Dokuz Eylul University Institute of health science, May 31, June 3, 2011.
2. Cancer Diseases Course for primary care physicians (Diagnosis, therapy and prevention) (II) 17-18 March 2011, Izmir-Turkey.
3. National Cellular Therapy and Regenerative Medicine Congress, Course in Flow Cytometry February 10, 2011, Izmir, Turkey.
4. Use of Experimental Animals Certificate Course Program, Dokuz Eylül University Animal Ethics Committee, May 2010.
5. Proteomics: Basic theoretical and practical knowledge as seminar participants. Dokuz Eylül University, organized by ARGE, May 2010.
6. 7th EACR-OECI Joint Training Course: Molecular Pathology Approach to Cancer, Amsterdam, Netherlands, 8 - 10 May 2017.

## REFERENCES

---

**1. Dr Erika Cecchin, PharmD, PhD**

Principle investigator at Experimental and Clinical Pharmacology Unit,  
Centro di Riferimento Oncologico, RCCS, National Cancer Institute, 33081 Aviano,  
Pordenone, Italy

Office phone : (+39) 0434-659667

Fax: (+39) 0434-659799

E-mail: [ececchin@cro.it](mailto:ececchin@cro.it)

**2. Yasemin Basbinar, MD, PhD, PhD**

Professor of Biochemistry and basic oncology  
Dokuz Eylul University Institute of Oncology,  
Department of Basic Oncology, Izmir- Turkey

Office Phone: + 90 232 4125890

Mobile: +90-533-334-3165

E- mail: [yasemin.baskin@deu.edu.tr](mailto:yasemin.baskin@deu.edu.tr),

[ybaskin65@gmail.com](mailto:ybaskin65@gmail.com)

**3. Hulya Ellidokuz, MD, PhD**

Professor of Preventive Oncology  
Dokuz Eylul University Institute of Oncology,  
Chair of Department of Preventive Oncology, Izmir-  
Turkey

Office Phone: + 90 232 412 58 89

GSM: +90-5426673722

E-mail: [hulya.ellidokuz@deu.edu.tr](mailto:hulya.ellidokuz@deu.edu.tr)

**4. Inga Reynisdottir, PhD**

Clinical Professor,  
Cell Biology Unit at the Pathology Department,  
Landspítali – The National University Hospital of Iceland,  
The Biomedical Center, Reykjavik, Iceland

Office Phone: +354 543-8058

E-mail: [ingar@landspitali.is](mailto:ingar@landspitali.is)